FPL 62064

Drug Profile

FPL 62064

Latest Information Update: 18 Jun 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fisons
  • Class Amines; Anti-inflammatories; Benzyl compounds; Pyrazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action 5-lipoxygenase inhibitors; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Crohn's disease; Inflammatory bowel diseases; Psoriasis; Rheumatic disorders; Ulcerative colitis

Most Recent Events

  • 18 Jun 1998 Discontinued-II for Crohn's disease in United Kingdom (Unknown route)
  • 18 Jun 1998 Discontinued-II for Inflammatory bowel disease in United Kingdom (Unknown route)
  • 26 Sep 1997 Discontinued-II for Psoriasis in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top